Seeing Is Believing
Currently out of the existing stock ratings of Charles Duncan, 338 are a BUY (88.71%), 38 are a HOLD (9.97%), 5 are a SELL (1.31%).
Analyst Charles Duncan works at CANTOR FITZGERALD with a stock forecast success ratio of 47.35% fulfilled within 301.15 days on average.
Charles Duncan’s has documented 763 price targets and ratings displayed on 55 stocks. The coverage is on Healthcare, Industrials sectors.
Most recent stock forecast was given on ACAD, ACADIA Pharmaceuticals at 30-Apr-2024.
Analyst best performing recommendations are on CLVS (CLOVIS ONCOLOGY).
The best stock recommendation documented was for RETA (REATA PHARMACEUTICALS) at 7/24/2023. The price target of $145 was fulfilled within 4 days with a profit of $35.33 (32.21%) receiving and performance score of 80.54.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Buy
37
$19.95 (117.01%)
42
6 days ago
25/34 (73.53%)
$20.29 (121.42%)
486
Buy
25
$7.95 (46.63%)
29
1 months 11 days ago
5/8 (62.5%)
$7.16 (40.13%)
26
Buy
30
$12.95 (75.95%)
40
1 months 23 days ago
16/19 (84.21%)
$10.44 (53.37%)
184
Buy
39
$21.95 (128.74%)
40
2 months 8 days ago
6/10 (60%)
$15.25 (64.21%)
94
Buy
33
$15.95 (93.55%)
33
2 months 8 days ago
8/19 (42.11%)
$9.25 (38.95%)
119
Which stock is Charles Duncan is most bullish on?
Which stock is Charles Duncan is most reserved on?
What Year was the first public recommendation made by Charles Duncan?